364 filings
Page 5 of 19
8-K
n3knj1v lc
18 Feb 20
Other Events
7:07am
8-K
n1ks6p3y
3 Feb 20
Other Events
7:21am
8-K
q9z823yx3
15 Jan 20
BioCryst Strengthens Commercial Rare Disease Leadership
7:15am
8-K
ls4dm
13 Jan 20
BioCryst to Provide Berotralstat and BCX9930 Program Updates at 38th Annual J.P. Morgan Healthcare Conference
6:32am
8-K
e4mp908jm0yen5jtnfa9
11 Dec 19
Other Events
7:28am
8-K
m1xowzb
21 Nov 19
Entry into a Material Definitive Agreement
1:16pm
8-K
0509 80zod
20 Nov 19
Entry into a Material Definitive Agreement
7:59am
8-K
g9j6ie
18 Nov 19
Other Events
9:36am
8-K
pocnjlyhg rtdzrqb1
8 Nov 19
Departure of Directors or Certain Officers
9:06am
8-K
qubxx 485hr
6 Nov 19
BioCryst Reports Third Quarter 2019 Financial Results and Upcoming Key Milestones
7:31am
8-K
mx0xxxkf rpi
5 Nov 19
BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks
7:02am
8-K
449ie
1 Nov 19
BioCryst Begins Phase 1 Trial With BCX9250, an Oral ALK-2 Inhibitor, for Treatment of Fibrodysplasia Ossificans Progressiva
7:32am
8-K
wez 00shyldux3
28 Oct 19
BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients
7:37am
8-K
7w4x6ebyjckctg93s me
26 Sep 19
U.S. Government Exercises Option for Additonal RapivabĀ® for Strategic National Stockpile
7:20am
8-K
ujmlmmv4 2z0ola9p49g
23 Sep 19
BioCryst Appoints Helen Thackray, M.D., to Board of Directors
9:45am
8-K
rvgluosj 3k9pwgpl0b
16 Sep 19
Entry into a Material Definitive Agreement
8:38am
8-K
equdz6
6 Aug 19
BioCryst Reports Second Quarter 2019 Financial Results
7:45am
8-K
hj1 y6zolqen2
1 Jul 19
Departure of Directors or Certain Officers
8:07am
8-K
402bzp opjm46j
1 Jul 19
BioCryst Appoints Megan Sniecinski Chief Business Officer
7:41am
8-K
akh55 t7k5hluibk2rvn
27 Jun 19
Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases
4:29pm